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Abstract
AIDS-associated, CCR5-tropic (R5) HIV-1 clones, isolated from a patient that never developed
CXCR4-tropic HIV-1, replicate to a greater extent and cause greater cytopathic effects than R5
HIV-1 clones isolated before the onset of AIDS. Previously, we showed that HIV-1 Env substantially
contributed to the enhanced replication of an AIDS clone. In order to determine if Nef makes a
similar contribution, we cloned and phenotypically analyzed nef genes from a series of patient
ACH142 derived R5 HIV-1 clones. The AIDS-associated Nef contains a series of residues found in
Nef proteins from progressors [1]. In contrast to other reports [1-3], this AIDS-associated Nef
downmodulated MHC-I to a greater extent and CD4 less than pre-AIDS Nef proteins. Additionally,
all Nef proteins enhanced infectivity similarly in a single round of replication. Combined with our
previous study, these data show that evolution of the HIV-1 env gene, but not the nef gene, within
patient ACH142 significantly contributed to the enhanced replication and cytopathic effects of the
AIDS-associated R5 HIV-1 clone.
Background
The nef gene of HIV-1 plays a pivotal role in the pathogen-
esis of AIDS [4-8]. For example, patients infected with nef-
deleted HIV-1 exhibited much slower progression to AIDS
[6,9-11]. The nef gene is important for viral replication in
mature T cells [12-16] and macrophages [14,17-19].
When thymocytes are infected, Nef plays a role in increas-
ing the cytopathic nature of the virus [20-24]. The impor-
tance of Nef is further corroborated by observations of
immune dysfunction in nef-transgenic mice [25-28].
Several functions have been assigned to Nef although the
role of each in disease progression has not been firmly
established (for reviews see: [21,29-37]). We chose to
focus on Nef's abilities to downmodulate CD4 [38] and
cell surface MHC-I A and B molecules [39,40], and its abil-
ity to enhance viral infectivity [12,41,42]. These functions
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have been well studied by several labs and in various cell
types and systems [17,43-50]. Nef mediated enhancement
of infectivity may be due to Nef downmodulation of cell
surface CD4, allowing more efficient Env incorporation
into HIV-1 particles [51,52]. Enhancement of infectivity
may also occur when Nef is present in CD4 negative pro-
ducer cells [12,53-56]. In this case, enhancement appears
to act at a post-entry, pre-integration step in the viral life
cycle [57,58] and may be related to interaction of the viral
pre-integration complex with the actin cytoskeleton [59].
Downmodulation of MHC-I A and B molecules protects
cells from lysis by HIV-1 specific cytotoxic T cells [40]. The
ability to avoid the immune system may be important in
establishment and maintenance of infection.
Kirchhoff and colleagues compared the predicted amino
acid sequences of Nef proteins from progressors with
those of non-progressors and found that certain residues
characterize Nef sequences from each type of patient [1].
When compared to non-progressor Nefs, progressor Nefs
were better able to downmodulate CD4 and less able to
downmodulate MHC-I molecules, and also may have an
increased ability to enhance HIV-1 infectivity [1,2].
Results
Previously, we demonstrated that the ACH142 AIDS clone
*E11 was better able to replicate and cause cytopathic
effects in human fetal thymus-liver grafts implanted in
severe combined immune deficient mice (SCID-hu thy/liv
mice), than the pre-AIDS clones, 8G9 and 32D2 [60]. In
an analysis parallel to this study, we examined the pheno-
types of the env genes from these clones and determined
that the AIDS associated env  likely contributed to the
observed replication differences between the AIDS clone
and the pre-AIDS clones [61]. In order to determine if nef
made a similar contribution, ACH142 nef  genes were
amplified from PHA-activated PBMC infected with the
HIV-1 clones ACH142-*E11, 32D2, and 8G9. The one
kilo base nef/LTR products were gel purified and inserted
into the pGEM-T vector (Promega). Six *E11, six 32D2
and three 8G9 full-length nef genes were sequenced.
Analysis of the predicted amino acid sequences of the con-
sensus Nef proteins revealed a high degree of conservation
among the patient ACH142 biological clones (Fig. 1).
When compared to sequence/function studies reported in
the literature, as reviewed in [31], no lack of function
mutations could be found, but three interesting differ-
ences were revealed. The AIDS Nef protein contains the
rare motif GEEE (amino acids 62–65), whereas the two
pre-AIDS proteins contain the more common EEEE
sequence at this position. This motif has been reported to
be important in MHC-I downmodulation. The *E11
sequence also has a significant lengthening of the N-ter-
minal portion of Nef caused by repetition of the four
amino acid sequence, AEPA (amino acids 23–26). Using
the analysis of Kirchhoff et al, we calculated the Nef pro-
gression score of each ACH142 Nef. A +1 score was
assigned for residues characteristic of progressors and a -1
score was assigned for those commonly found in non-pro-
gressors at the positions denoted by bold italic symbols
(Fig. 1). This number therefore reflects the degree of sim-
ilarity between each ACH142 Nef sequence and Nefs from
progressors or non-progressors at particular amino acid
positions. We found that the AIDS associated nef, *E11, is
more similar to progressor Nef sequences with a Nef pro-
gression score of +5 than are the pre-AIDS Nefs from the
same patient which had Nef progression scores of +2 and
+3.
To elucidate the significance of these differences and to
assign phenotypes to each Nef protein, we inserted each
consensus nef gene into an actin promoter driven expres-
sion vector (pA-nef). Next we analyzed the ability of each
Nef to downmodulate cell surface CD4 and MHC-I A2
molecules on the T lymphoblastoid cell line, SupT1. Elec-
troporation and flow cytometric analysis of SupT1 cells
bearing pA-nef expression vectors was done as previously
described [50]. Two μg of pCMV-EGFP and 10 μg of each
pA-nef expression plasmid, or empty pA vector were intro-
duced into SupT1 cells by electroporation. The cells were
then plated in 10 cm dishes and cultured for 24 hours.
Subsequently, the cells were incubated with CD4-PerCP
and MA2.1-PE monoclonal antibodies to detect CD4 and
the A2 allele of MHC-I by flow cytometry. Data were col-
lected with a FACSCalibur instrument and the GFP+ pop-
ulation was analyzed for CD4 and MHC-I surface
expression with CellQuest software.
Expression of consensus nef genes from the two pre-AIDS
clones, 8G9 and 32D2, induced the highest level of CD4
downmodulation, similar to that of the NL4-3 nef gene
(Fig. 2). The late stage *E11 consensus nef gene induced
significantly less CD4 downmodulation (p < 0.0001 by
Student's t-test). In contrast, the ability to downmodulate
MHC-I A2 molecules was similar for *E11 and NL4-3 nef
genes, while the nef genes from the earlier ACH142 clones
exhibited significantly less MHC-I downmodulation (p <
0.003 by Student's t-test). When increasing doses of Nef
expression plasmid were used in electroporation of SupT1
cells, this difference was heightened. In no case was the
*E11 Nef better able to downmodulate CD4 than the two
earlier clones' Nefs or NL4-3 Nef. Likewise, in no case
were the two pre-AIDS Nef alleles better able to down-
modulate MHC-I A2 molecules than the *E11 AIDS Nef.
Nef expression levels were similar for all three patient
ACH142 derived nef genes. The 8G9 and 32D2 Nefs were
expressed at 1.5 and 1.6 times higher levels than the *E11
Nef respectively, as determined by radiometric quantita-
tion of a Nef immunoblot (Fig. 2E).Retrovirology 2008, 5:42 http://www.retrovirology.com/content/5/1/42
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The contribution of each consensus nef  gene to HIV-1
infectivity was determined using the CD4 negative HIV-1
packaging cell line, 5BD.1 and the hygromycin resistance
gene-bearing HIV-1 derived vector, TR167 [56]. Cells were
co-transfected with pTR167 Δnef (5 μg), pCMV-Tat (2 μg)
and either the *E11, 32D2, 8G9 or NL4-3 pCMV-nef
expression vector (5 μg) to produce hygromycin resist-
ance-transducing HIV-1 vector particles. Vector stocks
were used to infect HeLa-CD4 cells; after two weeks of
selection with hygromycin, colonies were stained with
crystal violet and counted (Fig. 3). All nef genes studied
here significantly enhanced the infectivity of the vector
when compared to nef negative vectors (p < 0.001 by Stu-
dent's t-test). The 32D2 pre-AIDS nef enhanced infectivity
significantly more than the *E11 AIDS nef (p < 0.01 by
Student's t-test). Similar infectivity enhancement was
mediated by the 8G9 pre-AIDS nef, the *E11 AIDS nef and
NL4-3 nef. Nearly identical results were observed when
each patient nef was used to complement vectors created
with env genes from the same HIV-1 biological clone (data
not shown).
Discussion
Our results suggest that the AIDS associated nef gene stud-
ied here does not significantly contribute to the enhanced
replication and cytopathic effects of the AIDS associated
*E11 R5 HIV-1 clone for the following three reasons. It is
highly conserved at almost all known sites within the Nef
sequence that are implicated in functional interactions. It
does not downmodulate CD4 to a greater extent than pre-
AIDS Nefs, nor does it more greatly enhance infectivity in
a single round assay compared to the pre-AIDS Nefs from
the same patient. Combined with our previous study, we
conclude that Env, but not Nef contributes to the
enhanced replication of the R5, AIDS-associated HIV-1
clone ACH142-*E11 compared to two pre-AIDS R5 HIV-
1 clones derived from the same patient [61].
Previous studies indicated that Nef proteins with high
progression scores had enhanced ability to downmodu-
late CD4, reduced ability to downmodulate MHC-I and
increased ability to enhance HIV-1 replication compared
to Nef proteins with lower progression scores [1-3]. The
The R5 AIDS HIV-1 clone ACH142-*E11 Nef has a higher progression score than the Nefs from two patient ACH142 derived  pre-AIDS R5 HIV-1 clones, 32D2 and 8G9 Figure 1
The R5 AIDS HIV-1 clone ACH142-*E11 Nef has a higher progression score than the Nefs from two patient ACH142 derived 
pre-AIDS R5 HIV-1 clones, 32D2 and 8G9. A Clustal W alignment of predicted Nef amino acid sequences is shown. Gaps in 
the alignment are represented by a dash. Bold amino acid residues represent changes of interest between isolates. Numbers 
above the alignment represent the amino acid position in this alignment. Bold, italicized residues were used to calculate the Nef 
progression score according to the method of Kirchhoff et al [1]. Upper case bold italicized letters indicate residues that are 
more common in progressors. Lower case bold italicized letters indicate residues that are more common in non-progressors.Retrovirology 2008, 5:42 http://www.retrovirology.com/content/5/1/42
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The R5 AIDS Nef from HIV-1 clone *E11 does not down regulate CD4 more than the two pre-AIDS alleles from 32D2 and  8G9, but does downregulate MHC Class I more than the pre-AIDS Nefs Figure 2
The R5 AIDS Nef from HIV-1 clone *E11 does not down regulate CD4 more than the two pre-AIDS alleles from 32D2 and 
8G9, but does downregulate MHC Class I more than the pre-AIDS Nefs. SupT1 cells were electroporated with 10 μg of pA-
Nef expression vectors and 2 μg of pCMV-EGFP expression vector. Cells were analyzed by flow cytometry 24-hrs post-elec-
troporation. The fraction of control levels of cell surface CD4 (A and C) or MHC Class I A2 (B and D) expression in GFP+ 
cells are reported for each allele. C and D 2.5, 10 or 20 μg of pA-*E11 Nef (diamonds), pA-32D2 Nef (squares), or pA-8G9 
Nef (triangles) were  transferred to SupT1 cells by electroporation. The average of eight transfections for A and B or two 
transfections for C and D is shown. Error bars represent the standard errors of the mean. Samples denoted with asterisks 
were significantly different from the *E11 sample as determined by the Student's unpaired t-test (A and B) or by the Student's 
paired t-test (C and D). E Twenty μg of pA-Nef expression vectors were used for electroporation of SupT1 cells with 2 μg of 
pCMV-EGFP. Cells were lysed in sample buffer and analyzed by SDS-PAGE and western blot. The blot was probed with a pol-
yclonal rabbit anti-Nef serum followed by 125I-Protein A. The blot was then analyzed by phosphorimager and quantitated using 
ImageQuant software. Results from a representative experiment of three experiments performed are shown.Retrovirology 2008, 5:42 http://www.retrovirology.com/content/5/1/42
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Nef proteins of patient ACH142 derived R5 HIV-1 clones
displayed a chronological increase in Nef progression
score as predicted, but the phenotype of these genes dif-
fered from the predicted phenotypes described above. The
AIDS associated Nef protein studied here had a higher
progression score (+5) than the pre-AIDS Nef proteins
derived from the same patient (+2 and +3), but did not
show an increased ability to downmodulate CD4 or to
enhance infectivity. Moreover, the AIDS associated Nef
protein had greater ability to downmodulate MHC-I A2
molecules. This is likely not explained by differences in
Nef expression because the *E11 Nef downmodulated
MHC-I to a greater extent despite being expressed at a
slightly lower level. One explanation for the discrepancy
between our results and those previously reported by oth-
ers may be that nef genes from CXCR4-tropic (X4) HIV-1
isolates have the phenotypes previously reported [2,3] but
nefs from R5 HIV-1 clones show the phenotypes demon-
strated here. Most of the progressor nefs used in previous
studies were likely derived from X4 HIV-1 because
patients with X4 HIV-1 progress to AIDS more rapidly. In
contrast, all three nef  genes studied here were derived
from patient ACH142, who never developed X4 HIV-1
[60,61]. More analyses of nef genes from R5 HIV-1 clones
derived from progressors are needed to test the generality
of our observations.
Previous studies have shown that X4 HIV-1 isolates are
more sensitive to neutralization by soluble CD4 than R5
HIV-1 [62-64] and that X4 HIV-1 clones incorporate less
Env into their virions when cellular CD4 is not down-
modulated than R5 HIV-1 clones [52]. It is therefore likely
that downmodulation of CD4 has a greater impact on X4
HIV-1 replication than on R5 HIV-1 replication. R5 HIV-1
Nef may therefore have a greater positive effect on viral
replication by down-modulating cell surface MHC-I mol-
ecules and thereby protecting infected cells from lysis by
anti-HIV-1 cytotoxic T lymphocytes.
Moreover, because R5 HIV-1 clones preferentially infect
effector memory T cells and macrophages while X4 HIV-1
clones preferentially infect naïve T cells, nef genes in each
type of HIV-1 may evolve over the course of an infection
to better enhance replication in each respective cell type.
Determining whether such an evolution occurs may allow
us to find specific Nef interactions that occur preferen-
tially in macrophages or in memory or naïve T cells. In
particular, Nef's ability to activate T cells may be more
essential for X4 HIV-1, since naïve T cells are less easily
activated than memory T cells.
Our data lend support to the notion that Nef cannot
evolve over the course of disease to enhance all of its func-
tions. This is true for our study in which an AIDS-associ-
ated Nef was reduced in its ability to downmodulate CD4
and enhanced in its ability to downmodulate MHC I and
is also true for other studies where the reverse was found.
This supports a paradigm whereby increased Nef medi-
ated downmodulation of CD4 or MHC Class I molecules
correlates with a loss in the other function. This paradigm
may be created by structural constraints that limit the abil-
ity of Nef to perform both functions optimally or by com-
petition for limiting cellular factors necessary for both
processes. Determination of these constraints and/or fac-
tors will shed light on the role of Nef in HIV-1 replication
and pathogenesis.
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